Phosphorylation of P90RSK is Associated with Increased Response to Neoadjuvant Chemotherapy in ER-positive Breast Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Dec 11

PMID 23216670

Citations 9

Authors

Hyeong-Gon Moon

Jae Kyo Yi

Hee Sung Kim

Hea Young Lee

Kyung-Min Lee

Minju Yi

SooKyung Ahn

Hee-Chul Shin

Ji-Hyun Ju

Incheol Shin

Wonshik Han

Dong-Young Noh

Affiliations

Soon will be listed here.

Abstract

Background: The clinical implication of Ras/Raf/ERK pathway activity in breast cancer tissue and its association with response to chemotherapy is controversial. We aimed to explore the value of p90RSK phosphorylation, a downstram molecule of the pathway, in predicting chemotherapy response in breast cancer.

Methods: The expression of phosphorylated p90RSK (phospho-p90RSK) and chemotherapy response was measured in 11 breast cancer cell lines and 21 breast cancer tissues. The predictive value of phospho-p90RSK was validated in core needle biopsy specimens of 112 locally advanced breast cancer patients who received anthracycline and taxane-based neoadjuvant chemotherapy.

Results: In 11 breast cancer cell lines, the relative expression of phospho-p90RSK was inversely correlated with cell survival after doxorubicin treatment (p = 0.021). Similar association was observed in fresh tissues from 21 breast cancer patients in terms of clinical response. In paraffin-embedded, formalin-fixed tissues from core needle biopsy tissues from 112 patients, positive phospho-p90RSK expression was associated with greater tumor shrinkage and smaller post-chemotherapy tumor size. The association between phospho-p90RSK expression and chemotherapy response was more evident in estrogen receptor(ER)-positive tumors. The expression of phosphor-p90RSK did not show a significant relationship with the incidence of pCR. P90RSK silencing using siRNA did not affect the cancer cell's response to doxorubicin, and the expression of phospho-p90RSK was highly correlated with other Ras/Raf/ERK pathway activation.

Conclusion: Our results suggest that phospho-p90RSK expression, which reflects the tumor's Ras/Raf/ERK/p90RSK pathway activation can be a potential predictive marker for chemotherapy response in ER-positive breast cancer which needs further independent validation.

Citing Articles

Prognostic Protein Biomarker Screening for Thyroid Carcinoma Based on Cancer Proteomics Profiles.

Xie P, Yin Q, Wang S, Song D Biomedicines. 2024; 12(9).

PMID: 39335579 PMC: 11428938. DOI: 10.3390/biomedicines12092066.

Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion.

Lazarte J, Lamango N Biomedicines. 2024; 12(3.

PMID: 38540084 PMC: 10968070. DOI: 10.3390/biomedicines12030470.

Therapeutic targeting of p90 ribosomal S6 kinase.

Wright E, Lannigan D Front Cell Dev Biol. 2024; 11:1297292.

PMID: 38169775 PMC: 10758423. DOI: 10.3389/fcell.2023.1297292.

Increased levels of plasma neudesin in adult growth hormone deficiency and their relationship with plasma liver-expressed antimicrobial peptide-2 levels: a cross-sectional study.

Vergani E, Bruno C, Gavotti C, Oliva A, Curro D, Mancini A J Endocrinol Invest. 2022; 46(6):1187-1195.

PMID: 36495439 DOI: 10.1007/s40618-022-01974-5.

ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses.

Lannigan D Endocrinology. 2022; 163(9).

PMID: 35880639 PMC: 9337271. DOI: 10.1210/endocr/bqac106.

References

Boutros T, Chevet E, Metrakos P . Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev. 2008; 60(3):261-310. DOI: 10.1124/pr.107.00106. View

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

Small G, Somasundaram S, Moore D, Shi Y, Orlowski R . Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther. 2003; 307(3):861-9. DOI: 10.1124/jpet.103.055806. View

Moon H, Han W, Noh D . Comparable survival between pN0 breast cancer patients undergoing sentinel node biopsy and extensive axillary dissection: a report from the Korean Breast Cancer Society. J Clin Oncol. 2010; 28(10):1692-9. DOI: 10.1200/JCO.2009.25.9226. View

Ma Q, Guin S, Padhye S, Zhou Y, Zhang R, Wang M . Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer. 2011; 10:66. PMC: 3117816. DOI: 10.1186/1476-4598-10-66. View

Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z . Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005; 7(5):R753-64. PMC: 1242143. DOI: 10.1186/bcr1285. View

Moon H, Han W, Lee J, Ko E, Kim E, Yu J . Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009; 20(4):636-41. DOI: 10.1093/annonc/mdn683. View

Stratford A, Reipas K, Hu K, Fotovati A, Brough R, Frankum J . Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells. 2012; 30(7):1338-48. DOI: 10.1002/stem.1128. View

10.

Neve R, Chin K, Fridlyand J, Yeh J, Baehner F, Fevr T . A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6):515-27. PMC: 2730521. DOI: 10.1016/j.ccr.2006.10.008. View

11.

Xian W, Pappas L, Pandya D, Selfors L, Derksen P, de Bruin M . Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 2009; 69(6):2244-51. PMC: 11888581. DOI: 10.1158/0008-5472.CAN-08-3398. View

12.

Rastogi P, Anderson S, Bear H, Geyer C, Kahlenberg M, Robidoux A . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26(5):778-85. DOI: 10.1200/JCO.2007.15.0235. View

13.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

14.

Haagenson K, Wu G . The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 2010; 29(1):143-9. PMC: 4063276. DOI: 10.1007/s10555-010-9208-5. View

15.

Guise S, Braguer D, Carles G, Delacourte A, Briand C . Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res. 2001; 63(3):257-67. DOI: 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T. View

16.

McGlynn L, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C . Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res. 2009; 15(4):1487-95. DOI: 10.1158/1078-0432.CCR-07-4967. View

17.

Keam B, Im S, Koh Y, Han S, Oh D, Cho N . Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011; 11:452. PMC: 3224348. DOI: 10.1186/1471-2407-11-452. View

18.

Lucien F, Brochu-Gaudreau K, Arsenault D, Harper K, Dubois C . Hypoxia-induced invadopodia formation involves activation of NHE-1 by the p90 ribosomal S6 kinase (p90RSK). PLoS One. 2012; 6(12):e28851. PMC: 3246449. DOI: 10.1371/journal.pone.0028851. View

19.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

20.

Small G, Shi Y, Higgins L, Orlowski R . Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007; 67(9):4459-66. DOI: 10.1158/0008-5472.CAN-06-2644. View